Abstract Background The prospective WEARIT-II-EUROPE registry aimed to assess the
value of the wearable cardioverter-defibrillator (WCD) prior to potential ICD implantation in …

Aims Data on outcomes in patients using the wearable cardioverter-defibrillator (WCD)> 90
days are limited. We aimed to analyse the clinical course of patients with WCD use≤ 90 …

Abstract Background The WEARIT‐II Registry demonstrated efficacy and safety of the
wearable cardioverter defibrillator (WCD) for at‐risk cardiac patients. However, 1‐year …

Patients at high risk for sudden cardiac death (SCD) may benefit from wearable cardioverter
defibrillators (WCD) by avoiding immediate implantable cardioverter defibrillator (ICD) …

Aim The wearable cardioverter‐defibrillator (WCD) is used for temporary protection from
sudden cardiac death (SCD) in patients with newly diagnosed heart failure with reduced …

Background The wearable cardioverter-defibrillator (WCD) is used for temporary protection
of patients deemed to be at high risk for sudden death (SCD) not yet meeting indications for …

Background: The wearable cardioverter-defibrillator (WCD) is available for patients at high
risk for sudden cardiac death (SCD) when immediate implantable cardioverter-defibrillator …

Background—Prospective data on the safety and efficacy of the wearable cardioverter
defibrillator (WCD) in a real-world setting are lacking. The Prospective Registry of Patients …

Abstract Introduction The latest European Society of Cardiology Guidelines recommend
consideration of a wearable cardioverter-defibrillator (WCD) for patients with a poor left …

Background: This study evaluated the wearable cardioverter-defibrillator (WCD) for use and
effectiveness in preventing sudden death caused by ventricular tachyarrhythmia or …